{"disease":{"id":"adebrelimab-shr-1316","name":"adebrelimab shr 1316"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06607276","title":"Phase 2 Trial of Adjuvant Adebrelimab Combined With Capecitabine in High-Risk Resected Cholangiocarcinoma: ACHIEVE","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":122,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT07035392","title":"Adebrelimab + Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":32,"lead_sponsor_name":"Zhangzhou Municipal Hospital","has_results":false},{"nct_id":"NCT06506292","title":"A Phase II Trial of Perioperative Adebrelimab Combined With XELOX in Resectable Locally Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":25,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}